JP2022547537A5 - - Google Patents

Info

Publication number
JP2022547537A5
JP2022547537A5 JP2022515650A JP2022515650A JP2022547537A5 JP 2022547537 A5 JP2022547537 A5 JP 2022547537A5 JP 2022515650 A JP2022515650 A JP 2022515650A JP 2022515650 A JP2022515650 A JP 2022515650A JP 2022547537 A5 JP2022547537 A5 JP 2022547537A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
vegf antagonist
dose
composition according
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022515650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022547537A (ja
JP7828274B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058459 external-priority patent/WO2021048806A1/en
Publication of JP2022547537A publication Critical patent/JP2022547537A/ja
Publication of JP2022547537A5 publication Critical patent/JP2022547537A5/ja
Priority to JP2025260627A priority Critical patent/JP2026072102A/ja
Application granted granted Critical
Publication of JP7828274B2 publication Critical patent/JP7828274B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022515650A 2019-09-13 2020-09-11 眼疾患を治療するための方法 Active JP7828274B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025260627A JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899892P 2019-09-13 2019-09-13
US62/899,892 2019-09-13
US202062971405P 2020-02-07 2020-02-07
US62/971,405 2020-02-07
PCT/IB2020/058459 WO2021048806A1 (en) 2019-09-13 2020-09-11 Methods for treating ocular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025260627A Division JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2022547537A JP2022547537A (ja) 2022-11-14
JP2022547537A5 true JP2022547537A5 (cg-RX-API-DMAC7.html) 2023-08-23
JP7828274B2 JP7828274B2 (ja) 2026-03-11

Family

ID=72521675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022515650A Active JP7828274B2 (ja) 2019-09-13 2020-09-11 眼疾患を治療するための方法
JP2025260627A Pending JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025260627A Pending JP2026072102A (ja) 2019-09-13 2025-12-17 眼疾患を治療するための方法

Country Status (11)

Country Link
US (1) US12649781B2 (cg-RX-API-DMAC7.html)
EP (1) EP4028128A1 (cg-RX-API-DMAC7.html)
JP (2) JP7828274B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062279A (cg-RX-API-DMAC7.html)
CN (1) CN114375201A (cg-RX-API-DMAC7.html)
AU (1) AU2020347575A1 (cg-RX-API-DMAC7.html)
CA (1) CA3149706A1 (cg-RX-API-DMAC7.html)
IL (1) IL289436A (cg-RX-API-DMAC7.html)
MX (1) MX2022003101A (cg-RX-API-DMAC7.html)
TW (1) TW202116802A (cg-RX-API-DMAC7.html)
WO (1) WO2021048806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
TW202337496A (zh) * 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1802334E (pt) 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Vegf를 억제하는 안정하고 가용성인 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante
US20160220675A1 (en) 2013-09-11 2016-08-04 Glenn Abrahmsohn Hypertonic antimicrobial therapeutic compositions
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
ES2642723B1 (es) 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
MX2020009140A (es) 2018-03-16 2020-09-28 Novartis Ag Metodos para el tratamiento de enfermedades oculares.
CN113194993A (zh) 2018-12-18 2021-07-30 诺华股份有限公司 含高浓度抗vegf抗体的蛋白质溶液配制品
AU2020347575A1 (en) 2019-09-13 2022-03-17 Novartis Ag Methods for treating ocular diseases

Similar Documents

Publication Publication Date Title
JP2025169389A5 (cg-RX-API-DMAC7.html)
Campochiaro et al. Anti–vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside
US10266588B2 (en) Method of treating osteoarthritis with an antibody to NGF
IL277333B1 (en) VEGF antagonists for use in the treatment of diabetic macular edema
FI3795181T3 (fi) Amd:n hoito aav2-variantilla ja afliberseptillä
FI4364724T3 (fi) Korkean pitoisuuden VEGF-reseptorifuusioproteiinia sisältäviä formulaatioita
US20060293270A1 (en) Methods and compositions for treating ocular disorders
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
CA3025258C (en) Use of sirolimus to treat exudative age-related macular degeneration with persistent edema
JP2024519629A5 (cg-RX-API-DMAC7.html)
NZ596663A (en) Use of vegf antagonists in intraocular neovascular disease treatment
JP2021522180A5 (cg-RX-API-DMAC7.html)
Fang et al. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema
Bertschinger et al. Yoga can be dangerous—glaucomatous visual field defect worsening due to postural yoga
JP2018529766A5 (cg-RX-API-DMAC7.html)
US20070027102A1 (en) Methods and compositions for treating macular degeneration
Hwang et al. Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial
Mehta et al. Intravitreal bevacizumab for the treatment of refractory diabetic macular edema
Ober et al. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection
RU2010108395A (ru) Способ лечения центральных субретинальных кровоизлияний
Esteve et al. Coats’ disease with macular oedema responsive to aflibercept and argon laser
CN102872464A (zh) 一种新型脉络膜新生血管基因治疗药物及其用途
Lee et al. Angiographically documented macular ischemia after single bevacizumab for macular edema secondary to central retinal vein occlusion
Vidyashree et al. Clinical study: Evaluation of the effect of topical nepafenac on central foveal thickness and visual acuity post panretinal photocoagulation in diabetic retinopathy
Moraes et al. Epidemiological Analysis of Patients with Vitreoretinal Diseases Undergoing Intravitreal Therapy at a Referral Hospital in the State of Pará